

Title

Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the United States: Trends from 2016-2021.

Running Header: Trends in DMARD Use in Patients with Rheumatoid Arthritis in the US: 2016-2021.

Authors

Samuel K Peasah^{1,2} PhD MBA, Elizabeth CS Swart¹ MPH, Yan Huang MS¹, Sandra L Kane-Gill² PharmD MS, Amy L Seybert² PharmD, Urvashi Patel⁴ PhD MPH, Chronis Manolis³ RPh, Chester B Good^{1,2,3} MD MPH

Affiliations

1. Value-based Pharmacy Initiatives, Center for High-Value Health Care, UPMC Health Plan, Pittsburgh, PA, USA
2. School of Pharmacy, University of Pittsburgh, Pittsburgh, PA USA
3. Department of Pharmacy, UPMC Health Plan, Pittsburgh, PA USA
4. Evernorth Research Institute, Cigna Health, St. Louis, MO USA

Corresponding author

Samuel K Peasah, PhD, MBA.

Value-based Pharmacy Initiatives, Center for High-Value Health Care, UPMC Health Plan, US Steel Tower, 40th floor. 600 Grant Street. Pittsburgh, PA 15219, USA. Email: Peasahsk@upmc.edu Tel. 412-454-5129

Supplemental table and figures

STable 1: Demographics of new DMARD RA users of RA from 2017-2021

	VARIABLE	TOTAL (37,907)	2017 (6,762)	2018 (7,054)	2019 (8,213)	2020 (8,200)	2021 (7,678)
MEAN AGE	Age (yrs, SD)	64.0 (13.7)	62.3 (13.7)	63.5 (13.8)	63.7 (13.6)	63.8 (13.4)	66.3 (13.9)
AGE GROUP	Elderly (≥65yrs)	54.3	49.2	53.2	53.5	53.5	61.3
	Adults (18-64yrs)	45.7	50.8	46.8	46.5	46.5	38.7
SEX	Male	21.8	22.2	21.2	22.3	21.2	22.2
	Female	78.2	77.8	78.8	77.7	78.8	77.8
RACE	White	70.5	70.9	68.0	70.3	70.7	72.2
	Black	12.7	11.7	14.0	13.0	12.6	12.3
	Hispanic	14.4	14.7	15.4	14.1	14.3	13.3
	Asian	2.5	2.7	2.6	2.6	2.4	2.2
INSURANCE TYPE	Commercial	36.0	41.8	36.9	35.9	37.2	28.7
	Medicare	64.0	58.2	63.1	64.0	62.8	71.3
	EPO	4.7	4.7	4.7	4.9	4.8	4.2
	HMO	23.8	32.5	25.5	22.4	21.1	18.9
	IND	0.6	0.8	0.7	0.6	0.7	0.5
	OTH	42.0	29.7	38.1	42.6	43.7	53.8
	POS	24.3	26.7	25.4	24.7	25.2	19.5
	PPO	4.7	5.5	5.6	4.8	4.4	3.2
US REGION	Midwest	22.7	29.2	20.1	20.9	21.7	22.5
	Northeast	9.9	7.8	9.4	10.4	10.4	11.4
	South	48.2	43.0	51.4	49.9	48.5	47.5
	West	19.2	20.0	19.1	18.9	19.4	18.7




Figure 1: Trends in patients using triple therapy, MTX + Biologics, and Biologics only for prevalence DMARD users.




Figure 2: Trends in patients using triple therapy, MTX + Biologics, and Biologics only for new DMARD users.